November 14 - 16, 2017 - Complement-based Drug Development Summit 2017, Boston, MA, USA
The Complement-based Drug Development Summit will provide a comprehensive, end-to-end analysis of the research and development process in this space, spanning pre-clinical and clinical trial design through to gaining regulatory approval and upscaling manufacturing process to meet market demand.
The industry-dedicated meeting will provide an unparalleled opportunity for world leaders to share unique insights in the complement therapeutics space and collaborate to overcome barriers in drug development. Companies already participating include:
Alexion – Ra Pharma – Apellis – Bioverativ – GSK – Alnylam – Achillion – Novartis – ChemoCentryx – Annexon – Genentech – Regeneron – CSL Behring – Ionis – InflaRx – Ophthotech – Exsera Biolabs – Hemera Biosciences – Quidel – National Jewish Health – Charles River Laboratories – BioCryst – Comptech – Gemini Therapeutics – Kira – University of Colorado Denver – University of Lubeck – University of Amsterdam – Medical University of South Carolina
Thursday, November 16, 2017, 10:00
Developing a Highly Potent and Selective First-in-Class Anti-C5a Antibody for Treatment of Inflammatory Diseases
Niels Riedemann
CEO, InflaRX
Synopsis
Overview of Terminal Complement Activation and illustration of the Extrinsic Pathway for C5a Generation
The InflaRx technology: Making of IFX-1, a targeted highly potent and selective anti- C5a antibody
Performance of IFX-1 in humans and in patients
Targeted C5a-inhibition in human disease: First data of IFX-1 treatment in patients suffering from Hidradenitis Suppurativa